SCHEMBL29013347

SCHEMBL29013347

c1ccc2sc(-c3cccc4[nH]nnc34)cc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 2/20 0.42
▸ MAPKAPK2 P49137 3/20 0.39
▸ HSD17B1 P14061 1/20 0.38
▸ HSD17B2 P37059 1/20 0.38
▸ BRD4 O60885 1/20 0.38
▸ CREBBP Q92793 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ PIK3CA P42336 2/20 0.36
▸ PRKDC P78527 2/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ PIK3R1 P27986 1/20 0.36
▸ CYP19A1 P11511 1/20 0.35
▸ GABRA5 P31644 1/20 0.35
▸ NQO1 P15559 1/20 0.35
▸ NQO2 P16083 1/20 0.35
▸ TNIK Q9UKE5 1/20 0.34
▸ ATR Q13535 1/20 0.34
▸ ATRIP Q8WXE1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8787765 0.84 MAPK1 (0.48) BRD4PIK3CAPRKDCPIK3CD
SCHEMBL7081757 0.76 APP (0.41) APPMAPKAPK2HSD17B1HSD17B2BRD4
SCHEMBL3398344 0.74 KDM4E (0.51) APP
SCHEMBL30556736 0.74 METAP2 (0.38) BRD4TNIK
SCHEMBL31619990 0.74 METAP2 (0.38) BRD4TNIK
SCHEMBL19133572 0.74 APP (0.57) APPHSD17B1HSD17B2BRD4CREBBP
SCHEMBL10213947 0.72 KDR (0.51) APPMAPKAPK2PIK3CAPRKDCPIK3CD
SCHEMBL17145024 0.72 BCHE (0.41) —
SCHEMBL12854022 0.72 APP (0.55) APPHSD17B1HSD17B2BRD4CREBBP
SCHEMBL28284665 0.71 MGAM (0.41) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116234803-A Combinations of estrogen receptor degrading agents and cyclin-dependent kinase inhibitors for the treatment of cancer 冰洲石生物科技公司 2023-06-06 — — CN disclosed
Send feedback